Reckitt Denies Reported Product Recall in the Philippines

Reckitt ( (GB:RKT) ) just unveiled an announcement.

Reckitt Benckiser Group has refuted a media report suggesting it had been subject to a product recall in the Philippines, stating that the Mead Johnson Nutrition product cited, Enfamil ProSobee Simply Plant-Based Infant Formula, is neither registered nor marketed in that country. By swiftly correcting the record, the company aims to prevent reputational damage and consumer confusion in a sensitive product category, underscoring its focus on brand trust and regulatory compliance in key markets.

The most recent analyst rating on (GB:RKT) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on Reckitt stock, see the GB:RKT Stock Forecast page.

Spark’s Take on GB:RKT Stock

According to Spark, TipRanks’ AI Analyst, GB:RKT is a Outperform.

Reckitt’s overall stock score reflects strong financial performance and strategic initiatives that support growth, particularly in emerging markets. While the valuation is a concern, the company’s focus on profitability and shareholder returns through buybacks and dividends enhances its investment appeal.

To see Spark’s full report on GB:RKT stock, click here.

More about Reckitt

Reckitt Benckiser Group is a global consumer health and hygiene company whose portfolio includes brands such as Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish and Veet, focusing on science-backed products that support healthier, cleaner lives. The company positions itself around a mission to protect, heal and nurture in pursuit of a cleaner, healthier world, emphasizing expanded access to healthcare and education, sustainable innovation, and reducing environmental impact as part of its broader social and environmental commitments.

Average Trading Volume: 1,804,028

Technical Sentiment Signal: Buy

Current Market Cap: £40.43B

See more insights into RKT stock on TipRanks’ Stock Analysis page.